Our second project was phase I study to test the safety of autologous mesenchymal stem cells of bone marrow origin and expanded in vitro. We proved that these are safe in stage II and III of KOA. We also showed that these cells are capable in renovating the damaged knee cartilage as proved by MRI. This work is currently under publication and expected to be published before the end of 2017.
Our third project was a phase I safety study with inclusion similar to project 2 except that we used allogeneic Wharton Jelly mesenchymal stem cells expanded in vitro. The primary objective was safety. The project was completed successfully and we are in the process of analyzing the data. It seems this is a safe product with minimal adverse events.
Project four. Is a phase I study with similar inclusion to project 2 and 3. The source of mesenchymal cells is allogeneic fat aspirate expanded in vitro. The study is still accruing patients. The primary endpoint is safety. We expect to complete the study early 2018.